Thomas Stoops, MD
Orthopaedic Surgery · Indianapolis, INNPI 1023460987
Payments from drug & device makers
Across 60 payments — averaging $257.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Encore Medical, LP$11K
- MVP Orthopedics Inc$1K
- Osteoremedies, LLC$713
- Smith+Nephew$610
- Linkbio Corp$520
- Heron Therapeutics, Inc.$181
- plus $634 from 6 others
What the payments were for
- Consulting fees$4,09527%
- Speaking & faculty fees$1,50010%
- Travel & lodging$4,73831%
- Food & beverage$3,91225%
- Education$1,2008%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Encore Medical, LP | 29 | $11,430 |
| MVP Orthopedics Inc | 3 | $1,359 |
| Osteoremedies, LLC | 6 | $713 |
| Smith+Nephew | 8 | $610 |
| Linkbio Corp | 3 | $520 |
| Heron Therapeutics, Inc. | 2 | $181 |
| Zimmer Biomet | 2 | $178 |
| KCI USA, Inc. | 1 | $111 |
| Exsomed Corporation | 1 | $97 |
| Medtronic | 3 | $97 |
| Onkos Surgical, Inc. | 1 | $78 |
| Amgen | 1 | $73 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DJO SURGICAL$20,131
- Remedy Spacer$597
- Remedy Spectrum GV Spacer$582
- BioBrush$221
- Anthology$150
- REAL INTELLIGENCE$148
- Journey II$148
- Legion Revision$148
- OR3O Dual Mobility$137
- REDAPT$137
- Zynrelef$118
- Spectrum GV$117
- Osteoboost Select 10cc$117
- PREVENA$111
- BIOWASH Surgical Irrigation$104
- OsteoBoost Select 5cc$104
How this compares
$15,445 in reported general payments places this provider in the 70th percentile of 400 orthopaedic surgery providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cefadroxil | 54 | $840 |
| Celecoxib | 23 | $685 |
| Oxycodone Hcl | 45 | $314 |
| Omeprazole | 21 | $67 |
| Gabapentin | 13 | $47 |
| Tramadol Hcl | 13 | $31 |
| Meloxicam | 14 | $11 |
Paid to pharmacies, not to this prescriber.
Other orthopaedic surgery in Indianapolis
- David FisherIndianapolis$5.9M
- Michael BerendIndianapolis$4.1M
- Sanford KunkelIndianapolis$1.9M
- Hill HastingsIndianapolis$1.6M
- Michael CrossIndianapolis$1M
- Brian MullisIndianapolis$644K
- Dean MaarIndianapolis$589K
- Wesley LackeyIndianapolis$524K
- Russell SwannIndianapolis$135K
- Thomas FischerIndianapolis$117K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.